Interestingly, we found a significantly positive correlation between MIR200CHG expression and the IC50 value of irinotecan (a chemotherapy drug for colon and lung cancers) and lapatinib (a targeted therapy for HER2-positive breast cancer) (Supplementary Fig. 4a, b), suggesting the potential value of MIR200CHG expression to predict the sensitivities of the two drugs. This evidence concerns the gene ERBB2 and breast cancer.